Research
Hormonal
Tirzepatide reduces liver fat content and visceral adipose tissue in patients with Type 2 Diabetes.
If you have Type 2 Diabetes and are concerned about liver health, tirzepatide not only helps control blood sugar and weight but also significantly reduces liver fat, which is beneficial for overall metabolic health.
GoodSupportsHIGH confidence
Treatment with tirzepatide was associated with a significant reduction in liver fat content, visceral adipose tissue volume, and abdominal subcutaneous adipose tissue... Liver fat level decreased by an average of 8.09% in the tirzepatide group and only 3.38% in the insulin degludec group.
Why this rating
Based on a sub-analysis of a large RCT (SURPASS-3), showing consistent positive trends.
Source
New horizons in the management of metabolic diseases: Focus on the efficacy and safety of tirzepatide
T. Yu. Demidova et al. · FOCUS Endocrinology · 2025
DOI 10.62751/2713-0177-2025-6-3-03
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo, other GLP-1 agonists, and insulin.Strong
- Tirzepatide improves renal outcomes, including reducing the risk of macroalbuminuria and slowing the decline in estimated glomerular filtration rate (eGFR), in patients with Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →